Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

RAS mutations in human cancers: Roles in precision medicine
Avaniyapuram Kannan Murugan, Michèle Grieco, Nobuo Tsuchida
Seminars in Cancer Biology (2019) Vol. 59, pp. 23-35
Closed Access | Times Cited: 123

Showing 1-25 of 123 citing articles:

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
Ufuk Degirmenci, Mei Wang, Jiancheng Hu
Cells (2020) Vol. 9, Iss. 1, pp. 198-198
Open Access | Times Cited: 452
Ferroptosis in cancer: From molecular mechanisms to therapeutic strategies
Qian Zhou, Yu Meng, Daishi Li, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 153
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Yue Zhou, Lei Tao, Jiahao Qiu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 148
In-Cell Structural Biology by NMR: The Benefits of the Atomic Scale
François‐Xavier Theillet
Chemical Reviews (2022) Vol. 122, Iss. 10, pp. 9497-9570
Open Access | Times Cited: 81
The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy
Qinglong Ma, Wenyang Zhang, Kongming Wu, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 4
Dynamic Multilevel Regulation of EGFR, KRAS, and MYC Oncogenes: Driving Cancer Cell Proliferation Through (Epi)Genetic and Post-Transcriptional/Translational Pathways
Mário Šereš, Katarina Spacayova, Zdena Sulová, et al.
Cancers (2025) Vol. 17, Iss. 2, pp. 248-248
Open Access | Times Cited: 2
KRasG12C inhibitors in clinical trials: a short historical perspective
Lisa Goebel, Matthias Müller, Roger S. Goody, et al.
RSC Medicinal Chemistry (2020) Vol. 11, Iss. 7, pp. 760-770
Open Access | Times Cited: 121
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
Daolin Tang, Guido Kroemer, Rui Kang
Molecular Cancer (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 64
Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward?
Hidayati Husainy Hasbullah, Marahaini Musa
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 21, pp. 11941-11941
Open Access | Times Cited: 56
Binding Affinity Determination in Drug Design: Insights from Lock and Key, Induced Fit, Conformational Selection, and Inhibitor Trapping Models
Danislav S. Spassov
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 7124-7124
Open Access | Times Cited: 12
Recent nanotechnological interventions targeting PI3K/Akt/mTOR pathway: A focus on breast cancer
Varruchi Sharma, Añil Sharma, Vasu Punj, et al.
Seminars in Cancer Biology (2019) Vol. 59, pp. 133-146
Closed Access | Times Cited: 65
ERK2 Phosphorylates PFAS to Mediate Posttranslational Control of De Novo Purine Synthesis
Eunüs S. Ali, Umakant Sahu, Elodie Villa, et al.
Molecular Cell (2020) Vol. 78, Iss. 6, pp. 1178-1191.e6
Open Access | Times Cited: 56
Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B
Valentina Svicher, Romina Salpini, Lorenzo Piermatteo, et al.
Gut (2020) Vol. 70, Iss. 12, pp. 2337-2348
Open Access | Times Cited: 55
Resistance looms for KRAS G12C inhibitors and rational tackling strategies
Junmin Zhang, Jilei Zhang, Qing Liu, et al.
Pharmacology & Therapeutics (2021) Vol. 229, pp. 108050-108050
Closed Access | Times Cited: 45
KRAS: A Druggable Target in Colon Cancer Patients
Francesca Negri, Lorena Bottarelli, Gian Luigi de’Angelis, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 8, pp. 4120-4120
Open Access | Times Cited: 37
The transcription factor XBP1 in dendritic cells promotes the T H 2 cell response in airway allergy
Gui Yang, Xianhai Zeng, Xiao‐Rui Geng, et al.
Science Signaling (2023) Vol. 16, Iss. 791
Closed Access | Times Cited: 17
Targeting RAF dimers in RAS mutant tumors: From biology to clinic
Huanhuan Yin, Qiulin Tang, Hongwei Xia, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 5, pp. 1895-1923
Open Access | Times Cited: 7
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms
Xiaojuan Yang, Hong Wu
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 6
Adaptive response of resistant cancer cells to chemotherapy
Yi‐Jye Chern, Isabella T. Tai
Cancer Biology and Medicine (2020) Vol. 17, Iss. 4, pp. 842-863
Open Access | Times Cited: 40
Combination therapy with miR34a and doxorubicin synergistically inhibits Dox-resistant breast cancer progression via down-regulation of Snail through suppressing Notch/NF-κB and RAS/RAF/MEK/ERK signaling pathway
Xiaoxia Yang, Pengfei Shang, Bingfang Yu, et al.
Acta Pharmaceutica Sinica B (2021) Vol. 11, Iss. 9, pp. 2819-2834
Open Access | Times Cited: 35
Identification and Validation of T-cell Receptors Targeting RAS Hotspot Mutations in Human Cancers for Use in Cell-based Immunotherapy
Noam Levin, Biman C. Paria, Nolan R. Vale, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 18, pp. 5084-5095
Open Access | Times Cited: 34
Isocitrate Dehydrogenase IDH1 and IDH2 Mutations in Human Cancer: Prognostic Implications for Gliomas
Avaniyapuram Kannan Murugan, Ahmad Alzahrani
British Journal of Biomedical Science (2022) Vol. 79
Open Access | Times Cited: 23
Small molecular inhibitors for KRAS-mutant cancers
Xuan Wu, Wenping Song, Cheng Cheng, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 16
Role of RAS signaling in ovarian cancer
Lubna Therachiyil, Anjana Anand, Abdullah Azmi, et al.
F1000Research (2022) Vol. 11, pp. 1253-1253
Open Access | Times Cited: 21
Novel RAF‐directed approaches to overcome current clinical limits and block the RAS/RAF node
Rossella Scardaci, Ewa Berlinska, Pietro Scaparone, et al.
Molecular Oncology (2024) Vol. 18, Iss. 6, pp. 1355-1377
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top